Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
31 Mar 2021
Webinar recording on Phase 2b study results
Watch CEO Neil Clark and CFO Shaun Claydon discuss the 'outstanding' outcome of the trial for XF-73, their nasal gel in development to prevent post-surgical infection.
They also address multiple diverse questions from the investors' audience, and the video lasts 37 minutes in total.